Seres Therapeutics, Inc. (MCRB) Stock Rating Reaffirmed by Cantor Fitzgerald
Seres Therapeutics, Inc. (NASDAQ:MCRB)‘s stock had its “buy” rating reaffirmed by analysts at Cantor Fitzgerald in a research report issued to clients and investors on Wednesday.
A number of other research firms have also weighed in on MCRB. BidaskClub lowered Seres Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, August 11th. ValuEngine raised Seres Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, August 1st. Canaccord Genuity set a $20.00 price objective on Seres Therapeutics and gave the stock a “buy” rating in a research note on Monday, June 12th. Zacks Investment Research lowered Seres Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, August 8th. Finally, Cowen and Company reissued a “buy” rating on shares of Seres Therapeutics in a research note on Friday, May 19th. Three equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus target price of $17.00.
Shares of Seres Therapeutics (MCRB) opened at 14.03 on Wednesday. Seres Therapeutics has a 12 month low of $8.85 and a 12 month high of $15.09. The company has a 50-day moving average price of $13.28 and a 200-day moving average price of $11.05. The company’s market capitalization is $568.38 million.
Seres Therapeutics (NASDAQ:MCRB) last issued its quarterly earnings results on Thursday, August 3rd. The biotechnology company reported ($0.69) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.59) by $0.10. The firm had revenue of $3 million for the quarter, compared to analysts’ expectations of $3 million. Seres Therapeutics had a negative return on equity of 80.21% and a negative net margin of 441.38%. The firm’s revenue for the quarter was up .0% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.70) earnings per share. On average, analysts forecast that Seres Therapeutics will post ($2.48) EPS for the current fiscal year.
ILLEGAL ACTIVITY WARNING: This story was originally reported by Watch List News and is owned by of Watch List News. If you are accessing this story on another site, it was illegally stolen and republished in violation of U.S. & international copyright and trademark legislation. The original version of this story can be read at https://www.watchlistnews.com/seres-therapeutics-inc-mcrb-stock-rating-reaffirmed-by-cantor-fitzgerald/1535000.html.
Institutional investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. raised its position in shares of Seres Therapeutics by 1.2% in the second quarter. Vanguard Group Inc. now owns 1,585,026 shares of the biotechnology company’s stock valued at $17,911,000 after buying an additional 19,363 shares during the period. ARK Investment Management LLC raised its position in shares of Seres Therapeutics by 21.5% in the second quarter. ARK Investment Management LLC now owns 765,191 shares of the biotechnology company’s stock valued at $8,647,000 after buying an additional 135,276 shares during the period. JPMorgan Chase & Co. raised its position in shares of Seres Therapeutics by 15.9% in the first quarter. JPMorgan Chase & Co. now owns 370,225 shares of the biotechnology company’s stock valued at $4,172,000 after buying an additional 50,860 shares during the period. State Street Corp raised its position in shares of Seres Therapeutics by 12.0% in the second quarter. State Street Corp now owns 321,699 shares of the biotechnology company’s stock valued at $3,637,000 after buying an additional 34,393 shares during the period. Finally, Northern Trust Corp raised its position in shares of Seres Therapeutics by 16.2% in the second quarter. Northern Trust Corp now owns 235,766 shares of the biotechnology company’s stock valued at $2,664,000 after buying an additional 32,875 shares during the period. 74.76% of the stock is currently owned by institutional investors.
Seres Therapeutics Company Profile
Seres Therapeutics, Inc is a microbiome therapeutics platform company. The Company is engaged in developing a class of biological drugs, which is referred as Ecobiotic microbiome therapeutics. The Company’s drugs are designed to restore health by repairing the function of a dysbiotic microbiome. The Company is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome.
Receive News & Ratings for Seres Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.